JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

As reported by Stocks-Markets-Economic Times

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Stocks-Markets-Economic Times ↗

Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.

COMPANIES Maruti Suzuki among 8 large-cap stocks to hit 52-week lows and fall up to 12% in a month Stocks-Markets-Economic Times
COMPANIES Market wrap: SBI, HDFC Life, TCS, Infosys top gainers and losers on Nifty and Sensex on Thursday Stocks-Markets-Economic Times
INDIAN Quote of the day by Edward Thorp: "I think that we only get estimates of the distributions and that we can only be somewhat sure of the estimates. That makes the problems in the financial world much more difficult, I think, because you have these uncertainties in the distributions." Markets-Economic Times
INDIAN ‘Biggest crash in history has begun’: Rich Dad Poor Dad author Robert Kiyosaki sounds the alarm Markets-Economic Times
INDIAN Bitcoin trades near $75,000 as CLARITY Act setback weighs, Fed decision in focus Markets-Economic Times
INDIAN Benchmarks recover after recent sell-off; Nifty ends above 23,200 Share Market Today
INDIAN SS Retail IPO subscribed 1.44 times Share Market Today
INDIAN UGRO Capital raises Rs 380 cr via long term institutional funding Share Market Today

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

More from Market Samachar